Dean Y. Li - 03 Oct 2022 Form 4 Insider Report for RECURSION PHARMACEUTICALS, INC. (RXRX)

Role
Director
Signature
/s/ Nathan Hatfield, attorney-in-fact
Issuer symbol
RXRX
Transactions as of
03 Oct 2022
Transactions value $
$0
Form type
4
Filing time
05 Oct 2022, 21:15:54 UTC
Previous filing
06 Jul 2022
Next filing
05 Jan 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RXRX Class A Common Stock Award $0 +1,092 +0.18% $0.000000 620,112 03 Oct 2022 Direct F1
holding RXRX Class A Common Stock 1,315,000 03 Oct 2022 By Dean Y. Li 2021 GRAT F2
holding RXRX Class A Common Stock 1,422,048 03 Oct 2022 By Dean Li and Ruth Li Revocable Trust
holding RXRX Class A Common Stock 450,000 03 Oct 2022 By Dean Y. Li 2021 Family Trust
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares were issued pursuant to the Issuer's Outside Director Compensation Policy.
F2 In Forms filed dating back to January 3, 2022, holdings by the Dean Y. Li 2021 GRAT were incorrectly reported as duplicate line items. This Form 4 corrects those errors. The Dean Y. Li 2021 GRAT indirectly holds 1,315,000 shares of Class A Common Stock